Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elotuzumab - AbbVie/Bristol-Myers Squibb

Drug Profile

Elotuzumab - AbbVie/Bristol-Myers Squibb

Alternative Names: BMS-901608; Empliciti; HuLuc-63; PDL-063

Latest Information Update: 27 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Australasian Leukaemia & Lymphoma Group; Bristol-Myers Squibb
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD319 antigen modulators; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Smoldering multiple myeloma

Most Recent Events

  • 12 Dec 2023 Washington University School of Medicine, Bristol-Myers Squibb and Celgene suspends a phase II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Canada and USA, due to poor accual (NCT03030261)
  • 06 Oct 2023 Amgen in collaboration with Bristol-Myers Squibb and Hospital District of Helsinki and Uusimaa completes a phase II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Finland and Sweden (IV) (NCT03155100)
  • 29 Mar 2023 Bristol-Myers Squibb terminates a phase II trial as sponsor no longer providing drug for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03411031)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top